tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

JSPR Stock Latest News

Jasper Therapeutics Reports Q3 2025 Financial Results
Company AnnouncementsJasper Therapeutics Reports Q3 2025 Financial Results
16d ago
JSPR
Positive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating
PremiumRatings
Positive Outlook on Jasper Therapeutics: Strong Drug Efficacy and Financial Stability Support Buy Rating
16d ago
JSPR
Buy Rating Affirmed for Jasper Therapeutics Amid Promising Clinical Trial Results and Proactive Development Efforts
PremiumRatings
Buy Rating Affirmed for Jasper Therapeutics Amid Promising Clinical Trial Results and Proactive Development Efforts
16d ago
JSPR
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)
PremiumThe Fly
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29)
16d ago
JSPR
Jasper Therapeutics’ Briquilimab Study: Long-Term Safety and Market Implications
PremiumCompany Announcements
Jasper Therapeutics’ Briquilimab Study: Long-Term Safety and Market Implications
1M ago
JSPR
Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria
PremiumCompany AnnouncementsJasper Therapeutics Advances Briquilimab Study for Chronic Urticaria
1M ago
JSPR
Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP
Premium
The Fly
Jasper Therapeutics price target lowered to $6 from $12 at Citizens JMP
2M ago
JSPR
Jasper Therapeutics Announces $30 Million Public Offering
Premium
Company Announcements
Jasper Therapeutics Announces $30 Million Public Offering
2M ago
8K
JSPR
Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43
PremiumThe Fly
Jasper Therapeutics 11.67M share Spot Secondary priced at $2.43
2M ago
JSPR
Jasper Therapeutics announces common stock offering, no amount given
PremiumThe Fly
Jasper Therapeutics announces common stock offering, no amount given
2M ago
JSPR
Jasper Therapeutics price target lowered to $25 from $29 at UBS
PremiumThe Fly
Jasper Therapeutics price target lowered to $25 from $29 at UBS
3M ago
JSPR
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
PremiumRatings
Hold Rating on Jasper Therapeutics Amid Uncertainty in BEACON Study and Drug Development Timeline
3M ago
JSPR
Jasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures
PremiumCompany AnnouncementsJasper Therapeutics Faces Business Risks Amid Clinical Trial Delays and Competitive Pressures
3M ago
JSPR
Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating
Premium
Ratings
Jasper Therapeutics: Promising Clinical Data and Strategic Focus Drive Buy Rating
3M ago
JSPR
Jasper Therapeutics Reports Promising Q2 2025 Results
Premium
Company Announcements
Jasper Therapeutics Reports Promising Q2 2025 Results
3M ago
JSPR
Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)
PremiumThe Fly
Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)
3M ago
JSPR
Jasper Therapeutics Announces Major Corporate Reorganization
PremiumCompany Announcements
Jasper Therapeutics Announces Major Corporate Reorganization
5M ago
8K
JSPR
Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria
PremiumThe Fly
Jasper Therapeutics to reduce workforce by 50%, focus on Chronic Urticaria
5M ago
JSPR
RBC downgrades Jasper Therapeutics on questions about briquilimab
PremiumThe Fly
RBC downgrades Jasper Therapeutics on questions about briquilimab
5M ago
CLDX
JSPR
Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP
PremiumThe FlyJasper Therapeutics price target lowered to $12 from $70 at Citizens JMP
5M ago
JSPR
Jasper Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
Premium
The Fly
Jasper Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
5M ago
JSPR
Jasper Therapeutics downgraded to Market Perform from Outperform at BMO Capital
Premium
The Fly
Jasper Therapeutics downgraded to Market Perform from Outperform at BMO Capital
5M ago
JSPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >